MIM
CSTL icon

Macroview Investment Management’s Castle Biosciences CSTL Stock Holding History

Macroview Investment Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-450
Closed -$12.8K – 191
2024
Q3 		$12.8K Sell
450
-33
-7% -$840 0.01% 212
2024
Q2 		$10.5K Sell
483
-23
-5% -$513 0.01% 227
2024
Q1 		$11.2K Buy
506
+373
+280% +$8.12K 0.01% 244
2023
Q4 		$2.87K Sell
133
-448
-77% -$7.88K ﹤0.01% 464
2023
Q3 		$9.81K Buy
+581
New +$10.2K 0.01% 276

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Macroview Investment Management's CSTL Position: Q4 2024 in Review

Macroview Investment Management sold out of Castle Biosciences (CSTL) in Q4 2024, closing a stake of 450 shares — an estimated $12.8K sold.

Macroview Investment Management first reported a position in CSTL in Q3 2023 and held it in 5 quarters. The position peaked at $12.8K in Q3 2024. 197 funds tracked by Wall St. Rank hold CSTL as of Q4 2024.

  • Macroview Investment Management reported no remaining Castle Biosciences position as of Q4 2024 after selling out during the quarter.
  • Macroview Investment Management sold 450 Castle Biosciences shares in Q4 2024, an estimated $12.8K.
  • Macroview Investment Management first reported a position in Castle Biosciences in Q3 2023 and held it in 5 quarters.
  • Macroview Investment Management's Castle Biosciences position peaked at $12.8K in Q3 2024.
  • 197 funds tracked by Wall St. Rank held Castle Biosciences as of Q4 2024.

Based on Macroview Investment Management's 13F filing for Q4 2024, filed 31 Jan 2025.